Reducing complications of metabolic dysfunction-associated steatotic liver disease.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-01 Epub Date: 2025-05-14 DOI:10.1080/17474124.2025.2502549

Naohiro Wada, Michihiro Iwaki, Takashi Kobayashi, Atsushi Nakajima, Masato Yoneda

{"title":"Reducing complications of metabolic dysfunction-associated steatotic liver disease.","authors":"Naohiro Wada, Michihiro Iwaki, Takashi Kobayashi, Atsushi Nakajima, Masato Yoneda","doi":"10.1080/17474124.2025.2502549","DOIUrl":null,"url":null,"abstract":"Introduction: Complications from metabolic dysfunction-associated steatotic liver disease (MASLD) include liver-related and extrahepatic complications, and the all-cause mortality rate is significantly higher in patients with MASLD than in those without MASLD.Areas covered: We review the complications of MASLD and their management based on the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) guidelines as well as medical papers. For the papers, we focused on studies referenced in the EASL and AASLD guidelines. Additionally, a search was conducted in PubMed to gather relevant literature.Expert opinion: Identifying and managing MASLD early, before it progresses to cirrhosis, is crucial to reducing mortality rates, and collaboration among healthcare professionals, including dietitians, nurses, and physical therapists, is vital for comprehensive management. There is active development of new drugs for MASLD, and we hope that new treatments will be developed soon.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"577-588"},"PeriodicalIF":3.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2025.2502549","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Complications from metabolic dysfunction-associated steatotic liver disease (MASLD) include liver-related and extrahepatic complications, and the all-cause mortality rate is significantly higher in patients with MASLD than in those without MASLD.

Areas covered: We review the complications of MASLD and their management based on the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) guidelines as well as medical papers. For the papers, we focused on studies referenced in the EASL and AASLD guidelines. Additionally, a search was conducted in PubMed to gather relevant literature.

Expert opinion: Identifying and managing MASLD early, before it progresses to cirrhosis, is crucial to reducing mortality rates, and collaboration among healthcare professionals, including dietitians, nurses, and physical therapists, is vital for comprehensive management. There is active development of new drugs for MASLD, and we hope that new treatments will be developed soon.

查看原文本刊更多论文

减少代谢功能障碍相关脂肪变性肝病的并发症。

导语：代谢功能障碍相关脂肪变性肝病（MASLD）的并发症包括肝脏相关和肝外并发症，MASLD患者的全因死亡率明显高于无MASLD患者。涉及领域：我们根据欧洲肝脏研究协会（EASL）和美国肝脏疾病研究协会（AASLD）指南以及医学论文回顾了MASLD的并发症及其管理。对于论文，我们主要关注在EASL和AASLD指南中引用的研究。此外，在PubMed中进行检索，收集相关文献。专家意见：早期识别和管理MASLD，在其发展为肝硬化之前，对于降低死亡率至关重要，医疗保健专业人员（包括营养师、护士和物理治疗师）之间的合作对于全面管理至关重要。MASLD的新药物正在积极开发，我们希望新的治疗方法能够很快被开发出来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.